Patents by Inventor Barry A. Morgan

Barry A. Morgan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methionine aminopeptidase-2 inhibitors and methods of use thereof
    Publication number: 20050059585
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: May 2, 2003
    Publication date: March 17, 2005
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
  • Somatostatin agonists
    Patent number: 6864234
    Abstract: The present invention is directed to cyclic peptides of formula (I): X-A1-cyclo(D-Cys-A3-A4-Lys-A6-A7)-A8-Y, or a pharmaceutically acceptable salt thereof. The peptides bind selectively to the somatostatin subtype receptor type-5 and elicit an agonist effect from the somatostatin subtype receptors.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: March 8, 2005
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
    Inventors: Dean Sadat-Aalaee, Barry A. Morgan
  • Imidazolyl derivatives
    Patent number: 6852725
    Abstract: The present invention is directed to imidazolyl derivatives of the formula: where the substituents are defined in the specification, or a pharmaceutically acceptable salt thereof. The derivatives bind selectively to the somatostatin subtype receptors and elicit either an agonist or antagonist effect from the somatostatin subtype receptors.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: February 8, 2005
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S. A. S.
    Inventors: Christophe Alain Thurieau, Lydie Francine Poitout, Marie-Odile Galcera, Christophe Philippe Moinet, Thomas D. Gordon, Barry A. Morgan
  • Imidazolyl derivatives
    Publication number: 20040176379
    Abstract: The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonists or antagonists of somatostatin receptors.
    Type: Application
    Filed: February 4, 2004
    Publication date: September 9, 2004
    Inventors: Christopher Alain Thurieau, Lydie Francine Poitout, Marie-Odile Galcera, Christophe Philippe Moinet, Thomas D. Gordon, Barry A. Morgan
  • Somatostatin antagonists
    Publication number: 20040097418
    Abstract: The invention features somatostatin antagonists having a D-amino acid at the second residue.
    Type: Application
    Filed: November 13, 2003
    Publication date: May 20, 2004
    Applicant: Societe De Conseils De Recherches Et D'Applications Scientifiques, S.A.S.
    Inventors: David H. Coy, Barry Morgan, William Murphy
  • Somatostatin antagonists
    Patent number: 6703481
    Abstract: The invention features somatostatin antagonists having a D-amino acid at the second residue.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: March 9, 2004
    Assignees: The Administration of the Tulane Educational Fund, Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
    Inventors: David H. Coy, Barry Morgan, William Murphy
  • Beta-carboline compounds
    Publication number: 20040038970
    Abstract: The present invention is directed to compounds of formula (I) wherein the variables are defined in the specification, which bind to somatostatin receptors and block Na channels.
    Type: Application
    Filed: March 7, 2003
    Publication date: February 26, 2004
    Applicant: Societe de Conseils de Recherches etd' Application Scientifiques, S.A.S. a Paris, France corp.
    Inventors: Christophe Alain Thurieau, Lydie Francine Poitout, Marie-Odile Galcera, Christophe Philippe Moinet, Thomas D. Gordon, Barry A. Morgan, Dennis C. H. Bigg, Jacques Pommier
  • Farnesyl transferase inhibitors
    Patent number: 6673927
    Abstract: The present invention is directed to compounds of the wherein the variables are as defined in the specification. The compounds are useful for inhibiting farnesyl transferase and for the treatment of tumors and restenosis.
    Type: Grant
    Filed: November 20, 1996
    Date of Patent: January 6, 2004
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
    Inventors: Thomas D. Gordon, Barry A. Morgan
  • Transcription factor modulators and uses thereof
    Publication number: 20030224992
    Abstract: The present invention provides transcription factor modulators useful for modulating gene expression in a cell, as well as pharmaceutical compositions containing these transcription factor modulators. The present invention also provides methods for modulating gene transcription in a cell and methods of treating a subject suffering from a transcription factor-associated disorder, such as cancer, inflammatory disorders or autoimmune disorders.
    Type: Application
    Filed: March 14, 2003
    Publication date: December 4, 2003
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: John L. Joyal, Mark A. Findeis, Malcolm J. Kavarana, Barry Morgan, Malcolm L. Gefter
  • Somatostatin analog and uses thereof
    Publication number: 20030153494
    Abstract: Claimed is a somatostatin agonist according to formula (I),
    Type: Application
    Filed: November 21, 2002
    Publication date: August 14, 2003
    Inventors: Thomas D. Gordon, Barry A. Morgan, Michael D. Culler
  • &bgr;-carboline compounds
    Patent number: 6586445
    Abstract: The present invention is directed to compounds of the formula wherein the variables are defined in the specification, which bind to somatostatin receptors and block Na channels.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: July 1, 2003
    Assignee: Société de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
    Inventors: Christophe Alain Thurieau, Lydie Francine Poitout, Marie-Odile Galcera, Christophe Philippe Moinet, Thomas D. Gordon, Barry A. Morgan, Dennis C. H. Bigg, Jacques Pommier
  • Farnesyl transferase inhibitors
    Publication number: 20030119864
    Abstract: A family of compounds capable of inhibiting the activity of farnesyl transferase.
    Type: Application
    Filed: October 18, 2002
    Publication date: June 26, 2003
    Applicant: Biomeasure Incorporated, a Massachusetts corporation
    Inventors: Thomas D. Gordon, Barry A. Morgan
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20030109671
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: May 2, 2002
    Publication date: June 12, 2003
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20020151493
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: November 1, 2001
    Publication date: October 17, 2002
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • FARNESYL TRANSFERASE INHIBITORS
    Publication number: 20020013319
    Abstract: A family of compounds capable of inhibiting the activity of farnesyl transferase.
    Type: Application
    Filed: November 20, 1996
    Publication date: January 31, 2002
    Inventors: THOMAS D. GORDON, BARRY A. MORGAN
  • Somatostatin antagonists
    Patent number: 6262229
    Abstract: The invention features somatostatin antagonists having a D-amino acid at the second residue.
    Type: Grant
    Filed: May 13, 1997
    Date of Patent: July 17, 2001
    Assignees: Biomeasure Incorporated, The Administration of the Tulane Educational Fund
    Inventors: David H. Coy, Barry Morgan, William Murphy
  • Inhibition of H. pylori proliferation
    Patent number: 5968903
    Abstract: The present invention is directed to a method of using somatostatin or a somatostatin agonist to inhibit the proliferation of Helicobacter pylori (H. pylori), which comprises administering to a patient in need thereof an effective amount of said somatostatin or somatostatin agonist. Preferably, a somatostatin sub-type receptor 2 (SSTR-2) selective somatostatin agonist is administered in a method of this invention. The inhibition of H. pylori proliferation is useful in treating various gastroduodenal diseases such as peptic ulcers, gastric cancer and gastric lymphoma.
    Type: Grant
    Filed: May 7, 1998
    Date of Patent: October 19, 1999
    Assignee: Biomeasure, Incorporated
    Inventors: Hiroshi Kaneko, Terunori Mitsuma, Koichi Yamashita, Barry Morgan
  • Toy finger painting apparatus
    Patent number: 5676549
    Abstract: Toy painting apparatuses which provide means for finger painting a substrate without the user coming into direct contact with the paint. The painting apparatus has paint dispensing means and also provides a relatively thin, flexible, transparent, protective barrier between liquid paints that are dispensed onto the surface of a substrate and a user's fingers. The apparatus allows a user to apply paint to a substrate, such as paper, and manipulate the paint by smearing it with fingers, trowels, rollers and other similar implements which are moved across the surface of the barrier.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: October 14, 1997
    Assignee: Toy Biz, Inc.
    Inventors: Abraham A. Arad, Anne Pitrone, Barry Morgan
  • Azole-fused peptides and processes for preparation thereof
    Patent number: 5378803
    Abstract: Azole-fused peptides useful as Substance P antagonists and analgesics, for example ##STR1## wherein ##STR2## represents ##STR3## wherein X is O, S or NH and * is D, or as intermediates therefor are prepared by azole and peptide forming methods.
    Type: Grant
    Filed: July 10, 1992
    Date of Patent: January 3, 1995
    Assignee: Sterling Winthrop Inc.
    Inventors: Barry A. Morgan, Thomas D. Gordon, Philip E. Hansen, Jasbir Singh
  • Succinamide derivative matrix-metalloprotease inhibitors
    Patent number: 5256657
    Abstract: Compounds having the structural formula ##STR1## wherein X is HONH or HO and especially wherein the carbon atom bearing CH.sub.2 R.sup.1 has the R-configuration, the carbon atom bearing CH.sub.2 R.sup.2 has the S-configuration, R.sup.1 is isopropyl, R.sup.2 is 3-indolyl, m is 2, n is 0, p is 2 and R.sup.3 and R.sup.4 taken alone are each methyl or R.sup.3 and R.sup.4 taken together with N are morpholino and pharmaceutically acceptable acid addition salts or solvates or acid addition salts-solvates thereof, which are matrix-metalloprotease inhibitors useful in treatment of disease in which matrix-metalloprotease promoted connective tissue remodelling is a causative factor, for example, rheumatoid arthritis and cancer, and a method of preparation and method of use thereof and methods of preparation of intermediates therefor are disclosed.
    Type: Grant
    Filed: August 19, 1991
    Date of Patent: October 26, 1993
    Assignee: Sterling Winthrop, Inc.
    Inventors: Jasbir Singh, Barry A. Morgan, James A. Gainor, Thomas D. Gordon, Robert C. Wahl